Answer
During monotherapy, brentuximab vedotin antibody–drug conjugate has a terminal half-life of approximately 4–6 days, with approximately 4–5 days observed in the study of paediatric patients aged 7–17 years.
Sources for this answer
- Adcetris 50 mg powder for concentrate for solution for infusionTakeda UK Ltd · emc · SmPC §5.2 Pharmacokinetic properties · Version 33Document updated
Sources checked